Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2023-02-08 10:03 am Purchase | 13G | ARCUTIS BIOTHERAPEUTICS INC CO ARQT | STATE STREET CORP STT | 3,679,385 6.04% | 3,679,385 (New Position) | View |
| 2023-02-03 4:27 pm Purchase | 13G | ARCUTIS BIOTHERAPEUTICS INC CO ARQT | BlackRock Inc. BLK | 5,214,258 8.6% | 900,394 (+20.87%) | View |
| 2022-08-26 4:12 pm Sale | 13D | ARCUTIS BIOTHERAPEUTICS INC CO ARQT | ORBIMED ADVISORS LLC | 2,828,356 4.7% | -318,368 (-10.12%) | View |
| 2022-08-09 3:11 pm Purchase | 13D | ARCUTIS BIOTHERAPEUTICS INC CO ARQT | Frazier Life Sciences VIII L.P. | 8,745,318 14.6% | 263,411 (+3.11%) | View |
| 2022-08-08 4:49 pm Unchanged | 13D | ARCUTIS BIOTHERAPEUTICS INC CO ARQT | Bain Capital Life Sciences Fund L.P. | 2,721,436 4.5% | 0 (Unchanged) | View |
| 2022-08-08 4:26 pm Sale | 13D | ARCUTIS BIOTHERAPEUTICS INC CO ARQT | ORBIMED ADVISORS LLC | 3,146,724 5.4% | -387,813 (-10.97%) | View |
| 2022-06-28 4:22 pm Sale | 13D | ARCUTIS BIOTHERAPEUTICS INC CO ARQT | ORBIMED ADVISORS LLC | 3,534,537 6.9% | -306,027 (-7.97%) | View |
| 2022-05-27 4:19 pm Sale | 13D | ARCUTIS BIOTHERAPEUTICS INC CO ARQT | Bain Capital Life Sciences Fund L.P. | 2,721,436 5.3% | -888,360 (-24.61%) | View |
| 2022-04-08 5:20 pm Sale | 13D | ARCUTIS BIOTHERAPEUTICS INC CO ARQT | ORBIMED ADVISORS LLC | 3,840,564 7.6% | -427,000 (-10.01%) | View |
| 2022-02-14 4:27 pm Purchase | 13G | ARCUTIS BIOTHERAPEUTICS INC CO ARQT | Point72 Asset Management L.P. | 2,657,962 5.3% | 107,226 (+4.20%) | View |
| 2022-02-09 09:09 am Purchase | 13G | ARCUTIS BIOTHERAPEUTICS INC CO ARQT | FMR LLC | 7,544,212 14.999% | 999,048 (+15.26%) | View |
| 2022-02-03 4:41 pm Purchase | 13G | ARCUTIS BIOTHERAPEUTICS INC CO ARQT | BlackRock Inc. BLK | 4,313,864 8.6% | 1,418,810 (+49.01%) | View |
| 2021-12-15 5:14 pm Purchase | 13G | ARCUTIS BIOTHERAPEUTICS INC CO ARQT | Point72 Asset Management L.P. | 2,550,736 5.1% | 2,550,736 (New Position) | View |
| 2021-05-12 5:27 pm Sale | 13D | ARCUTIS BIOTHERAPEUTICS INC CO ARQT | Frazier Life Sciences VIII L.P. | 8,481,907 16.9% | -2,084,883 (-19.73%) | View |
| 2021-02-09 11:14 am Purchase | 13D | ARCUTIS BIOTHERAPEUTICS INC CO ARQT | Frazier Life Sciences VIII L.P. | 10,566,790 21.7% | 24,000 (+0.23%) | View |
| 2021-02-08 9:54 pm Unchanged | 13D | ARCUTIS BIOTHERAPEUTICS INC CO ARQT | ORBIMED ADVISORS LLC | 4,267,564 8.8% | 0 (Unchanged) | View |
| 2021-02-08 5:00 pm Unchanged | 13D | ARCUTIS BIOTHERAPEUTICS INC CO ARQT | Bain Capital Life Sciences Fund L.P. | 3,609,796 7.4% | 0 (Unchanged) | View |
| 2021-02-08 10:15 am Purchase | 13G | ARCUTIS BIOTHERAPEUTICS INC CO ARQT | FMR LLC | 6,545,164 14.999% | 2,486,155 (+61.25%) | View |
| 2021-02-02 3:13 pm Purchase | 13G | ARCUTIS BIOTHERAPEUTICS INC CO ARQT | BlackRock Inc. BLK | 2,895,054 6.6% | 2,895,054 (New Position) | View |
| 2020-10-07 5:08 pm Purchase | 13D | ARCUTIS BIOTHERAPEUTICS INC CO ARQT | ORBIMED ADVISORS LLC | 4,267,564 9.9% | 200,000 (+4.92%) | View |